A Novel Strategy for the Treatment of Chronic Pain: Antagonising PAR2 with a Monoclonal Antibody

September 20, 2018 @ 2-3pm ET
Session 8 of the 2018 Drug Design and Delivery Symposium


A profile of a woman with a digital overlay of a brain across her head

Current therapeutic options for the treatment of chronic pain states are inadequate. Proteinase-activated receptor (PAR)-2 involvement in pain signaling is well known, yet suitable antagonists to the GPCR have proven hard to identify. Join Pete Thornton, a Senior Scientist on the Neuroscience Biology Team at AstraZeneca, during this free interactive webinar as he presents data describing a new approach to blocking the receptor signaling pathway which could deliver a novel therapeutic option for chronic pain patients.

What You Will Learn

  • What is the role of the GPCR proteinase-activated receptor (PAR)-2 in chronic pain                     
  • Why improving anti-PAR2 IgG pharmacokinetic profiles is possible by selecting for pH-dependent binding states  
  • Why MEDI0618 is a novel anti-PAR2 IgG with high potency

Webinar Details 

Benefits of Membership

  • ACS Webinars Archive: Every one of our 200+ past webinars available on demand
  • Save Money: Members receive discounts on meetings, development courses and more!
  • Access to SciFinder®: Members receive 25 complimentary SciFinder® research activities per year

The Fine Print

ACS Webinars® does not endorse any products or services. The views expressed in this presentation are those of the presenters and do not necessarily reflect the views or policies of the American Chemical Society.

ACS Webinars logo

Experts

Pete Thornton
AstraZeneca

Nurulain Zaveri
Astraea Therapeutics

Co-Produced By